Anya Schiess
Co-Managing Partner @ JP Morgan
San Francisco, United States
Anya Schiess is a seed investor at JP Morgan in San Francisco focused on SaaS and Software. Anya Schiess is the Co-Managing Partner at JP Morgan. She attended the University of Pennsylvania and Princeton University.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Anya Schiess invests in
SaaSSoftwareAnalyticsArtificial IntelligenceGenetics
Stages Anya Schiess invests in
SeedSeries AFunding Round
Countries Anya Schiess invests in
United States
Investment Focus
Industry
- SaaS 2 (25%)
- Software 2 (25%)
- Analytics 2 (25%)
- Artificial Intelligence 2 (25%)
- Genetics 1 (13%)
Stage
- Seed 3 (38%)
- Series A 2 (25%)
- Funding Round 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cornerstone AI
|
Cornerstone AI provides the cleaning and standardizing of data and too analyzing it. each had built internal tooling to take steps to improve this process. | $5M / Seed / Oct 30, 2024 | |
WhizAI
|
WhizAI is the first and only AI-powered analytics platform purpose-built for life sciences and healthcare. It puts insights directly into the hands of business users empowering decision-makers to drive more informed and faster business decisions at lower cost. With its deep understanding of the life sciences and healthcare domains and user intent,the platform delivers insights without the delays of traditional BI dashboards. Fast, easy, and scalable, WhizAI is transforming analytics with artificial intelligence optimized for life sciences and healthcare making WhizAI the trusted partner of choice at top global companies.Simply ask a question about sales, market access, patient services, or clinical trials -- and WhizAI answers it instantly. WhizAI's conversational interface allows users to simply talk to the enterprise data giving them complete autonomy to drill into every level of detail along with real-time updates. WhizAI’s advanced machine learning algorithms scan entire data sets to deliver proactive alerts and automatically surface anomalies, easily pinpointing stagnating sales, market share changes, patient drop-offs and much more.WhizAI enjoys nearly 100% adoption by business users, contributes to a 60% reduction in calls to IT and a 50% reduction in operational overhead within the first few months of implementation. | $6M / Series A / Oct 25, 2022 | |
|
Cornerstone AI
|
Cornerstone AI provides the cleaning and standardizing of data and too analyzing it. each had built internal tooling to take steps to improve this process. | $5M / Seed / Jul 18, 2022 | |
Sprockets
|
Sprockets’ sophisticated software evaluates potential hires based on the traits of a company’s best employees to determine the right candidate in just a few minutes. There is no guesswork, frustration, or the expense of high turnover. It’s not magic — it’s logic. | $10M / Series A / Mar 28, 2022 | |
|
WhizAI
|
WhizAI is the first and only AI-powered analytics platform purpose-built for life sciences and healthcare. It puts insights directly into the hands of business users empowering decision-makers to drive more informed and faster business decisions at lower cost. With its deep understanding of the life sciences and healthcare domains and user intent,the platform delivers insights without the delays of traditional BI dashboards. Fast, easy, and scalable, WhizAI is transforming analytics with artificial intelligence optimized for life sciences and healthcare making WhizAI the trusted partner of choice at top global companies.Simply ask a question about sales, market access, patient services, or clinical trials -- and WhizAI answers it instantly. WhizAI's conversational interface allows users to simply talk to the enterprise data giving them complete autonomy to drill into every level of detail along with real-time updates. WhizAI’s advanced machine learning algorithms scan entire data sets to deliver proactive alerts and automatically surface anomalies, easily pinpointing stagnating sales, market share changes, patient drop-offs and much more.WhizAI enjoys nearly 100% adoption by business users, contributes to a 60% reduction in calls to IT and a 50% reduction in operational overhead within the first few months of implementation. | $4M / Seed / Jul 27, 2020 | |
|
WhizAI
|
WhizAI is the first and only AI-powered analytics platform purpose-built for life sciences and healthcare. It puts insights directly into the hands of business users empowering decision-makers to drive more informed and faster business decisions at lower cost. With its deep understanding of the life sciences and healthcare domains and user intent,the platform delivers insights without the delays of traditional BI dashboards. Fast, easy, and scalable, WhizAI is transforming analytics with artificial intelligence optimized for life sciences and healthcare making WhizAI the trusted partner of choice at top global companies.Simply ask a question about sales, market access, patient services, or clinical trials -- and WhizAI answers it instantly. WhizAI's conversational interface allows users to simply talk to the enterprise data giving them complete autonomy to drill into every level of detail along with real-time updates. WhizAI’s advanced machine learning algorithms scan entire data sets to deliver proactive alerts and automatically surface anomalies, easily pinpointing stagnating sales, market share changes, patient drop-offs and much more.WhizAI enjoys nearly 100% adoption by business users, contributes to a 60% reduction in calls to IT and a 50% reduction in operational overhead within the first few months of implementation. | $4M / Seed / Jul 27, 2020 | |
Wootcloud
|
WootCloud is the only smart device security platform that uncovers unmanaged devices on both the radio and network spectrum, and analyzes over 300 device parameters to generate device risk scores. This helps organizations discover gaps in their device risk posture and the opportunity to close these gaps. | $3.6M / Seed / Apr 01, 2019 | |
Invitae
|
Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people.Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, fasterturnaround time, and a lower price than most single-gene diagnostic tests today.What’s our plan? It takes three steps:--Make genetic testing more affordable and accessible than ever before.--Build a secure and trusted genome management infrastructure.--Design a new global community for sharing genetic information to advance science and medicine.Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people. | $3.6M / Sep 15, 2010 |
Co-Investors
About JP Morgan
JP Morgan is a financial institution. It offers asset management, commercial banking, investment banking, merchant services, securities services, treasury and payments, and wealth management services.
JP Morgan Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Yvonne McCague
Managing Director, Innovation Economy
|
|||
|
Ana Capella
Managing Director
|
|||
|
Andrew Joo
Analyst, IB
|
|||
Andy Dacy
Managing Director
|
|||
|
Anya Schiess
Co-Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Artificial intelligence Investors
40,702 investors
Biotech Investors
21,775 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
Health Care VC Funds
32,370 investors
Artificial intelligence VC Funds
27,398 investors
FAQ
What does Anya Schiess invest in?
Anya Schiess invests primarily in SaaS, Software and Analytics startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Anya Schiess last invest?
The most recent investment recorded for Anya Schiess closed in Oct 2024. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
